Allergan plc, of Dublin, said the FDA approved its supplemental new drug application to update the label for Dalvance (dalbavancin) for injection. The expanded label will include a single dose administered as a 30-minute intravenous infusion for the treatment of acute bacterial skin and skin structure infections (ABSSSIs) caused by designated susceptible gram-positive bacteria in adults, including infections caused by methicillin-resistant Staphylococcus aureus. Dalvance was first approved in May 2014 for the treatment of ABSSSI in adults. (See BioWorld Today, May 27, 2014.)